LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Home・Elenco Azioni・Coherus Oncology Inc

Coherus Oncology Inc

Chiusa

SettoreSettore sanitario

1.47 -3.29

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

1.46

Massimo

1.52

Metriche Chiave
By Trading Economics
Entrata	-278M -37M
Vendite	-438K 12M
P/E Media del settore	3.509 49.888
EPS	-0.25
Margine di Profitto	-300.041
Dipendenti	145
EBITDA	7.9M -35M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+442.76% upside

Dividendi
By Dow Jones
Utili prossimi	6 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-17M 242M
Apertura precedente	4.76
Chiusura precedente	1.47

Notizie sul Sentiment di mercato

By Acuity

50%

154 / 344 Classifica in Healthcare

Coherus Oncology Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 giu 2026, 23:22 UTC

Utili

I principali Market Mover

Broadcom Shares Slide Despite Jump in 2Q Revenue on AI Chip Demand -- Update

3 giu 2026, 23:09 UTC

Azioni calde

Stocks to Watch: Broadcom, CrowdStrike, PVH, Petco

3 giu 2026, 20:51 UTC

Utili

Costco Reports 15% Sales Growth in May

3 giu 2026, 20:43 UTC

Utili

Broadcom 2Q Revenue Climbs on AI Chip Demand

3 giu 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Fall Amid Renewed Concerns About Iran Conflict -- Market Talk

3 giu 2026, 23:48 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

3 giu 2026, 23:35 UTC

Discorsi di Mercato

Oil Futures Fall on Possible Technical Correction -- Market Talk

3 giu 2026, 23:15 UTC

Discorsi di Mercato

Utili

Five Below, Broadcom and Crowdstrike Fall Despite Solid Results -- Market Talk

3 giu 2026, 22:08 UTC

Azioni calde

After-Hours Stocks to Watch: CrowdStrike, Broadcom, Five Below -- WSJ

3 giu 2026, 21:54 UTC

Discorsi di Mercato

Correction to Oil Futures Rise on Concerns About U.S.-Iran Talks Article on June 1

3 giu 2026, 21:18 UTC

Utili

Broadcom's Non-AI Semiconductor Revenue Rose 6% in 2Q, CEO Says

3 giu 2026, 21:15 UTC

Utili

Broadcom CEO: Google Partnership Continues to Be 'Very Substantial'

3 giu 2026, 21:13 UTC

Utili

Broadcom CEO Expects AI Semiconductor Revenue Growth to Continue in Fiscal 2028

3 giu 2026, 21:13 UTC

Utili

Broadcom Continues to Expect AI Semiconductor Revenue of More Than $100B in 2027, CEO Says

3 giu 2026, 21:12 UTC

Utili

Broadcom Expects AI Semiconductor Revenue of $56B This Year, CEO Says

3 giu 2026, 21:09 UTC

Utili

Broadcom CEO: Networking Made Up Almost 40% of AI Revenue in 2Q

3 giu 2026, 21:03 UTC

Utili

Broadcom Stock Falls After Earnings. Here's Why. -- Barrons.com

3 giu 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

3 giu 2026, 20:43 UTC

Utili

CrowdStrike Stock Falls Despite Earnings Beat -- Barrons.com

3 giu 2026, 20:39 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 4th Update

3 giu 2026, 20:37 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 3rd Update

3 giu 2026, 20:35 UTC

Utili

Broadcom Stock Falls Despite Record Results -- Barrons.com

3 giu 2026, 20:21 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- 2nd Update

3 giu 2026, 20:17 UTC

Utili

Broadcom 2Q Semiconductor Solutions Revenue $15B >AVGO

3 giu 2026, 20:17 UTC

Utili

Broadcom Sees 3Q Semiconductor Revenue From AI $16B >AVGO

3 giu 2026, 20:15 UTC

Acquisizioni, Fusioni, Takeovers

Bill Ackman's Pershing Square Set To Make $600 Million on Universal Stake -- Update

3 giu 2026, 20:15 UTC

Utili

Broadcom 2Q Adj EPS $2.44 >AVGO

3 giu 2026, 20:15 UTC

Utili

Broadcom 2Q EPS $1.91 >AVGO

3 giu 2026, 20:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

3 giu 2026, 20:15 UTC

Utili

Broadcom 2Q Rev $22.19B >AVGO

Confronto tra pari

Modifica del prezzo

Coherus Oncology Inc Previsione

Obiettivo di Prezzo

By TipRanks

442.76% in crescita

Previsioni per 12 mesi

Media 8.25 USD 442.76%

Alto 12 USD

Basso 4 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Coherus Oncology Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

5 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 5 che hanno fornito valutazioni azionarie a Coherus Oncology Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

154 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Coherus Oncology Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.